ArticleAnnals of nuclear medicine2026
Whole-body biodistribution of [
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objective[18F]SMBT-1 is a selective and reversible monoamine oxidase B (MAO-B) radiotracer used for astrogliosis imaging. This study aimed to observe the whole-body biodistribution of [¹⁸F]SMBT-1 and evaluate peripheral MAO-B expression in healthy human volunteers using dynamic positron emission tomography (PET) imaging.
methodsSix healthy subjects (four males, two females; age range: 21–63 years) underwent nine dynamic PET scans over 5.5 h after [18F]SMBT-1 injection. The first five emission scans were acquired consecutively in a single session within 30 min (min) of post-injection (p.i.). The remaining four emission scans were performed at 70–110, 150–180, 220–250, and 290–330 min p.i. Regions of interest (ROIs) were manually drawn on the co-registered PET and magnetic resonance imaging (MRI) for the selected organs to extract mean standardized uptake values (SUVmean) and generate time-activity curves (TACs).
resultsA significantly high early uptake of [18F]SMBT-1 was observed in the kidneys, liver, heart, and stomach between 5 and 30 min p.i. The kidneys showed the highest early peak at 5 min p.i. (SUVmean = 14.2 ± 3.5). The gallbladder and intestines exhibited a delayed uptake pattern, with the gallbladder SUVmean increasing substantially from 9.0 ± 4.2 at 30 min to 123.7 ± 53.4 at 330 min. No significant differences in tracer uptake patterns were observed across participants.
conclusion[¹⁸F]SMBT-1 exhibited favorable reversible kinetics in the whole-body biodistribution assessment, confirming its established utility for imaging reactive astrocytes and indicating its potential for future applications in systemic high MAO-B-related pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.